Zambon Company S.p.A.
https://www.zambonpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zambon Company S.p.A.
First Clinical Safety Study Starts For Newron's Evenamide
Following safety issues raised by the US FDA, no toxicity concerns have emerged in preclinical studies of Newron’s candidate schizophrenia therapy, evenamide, and a clinical safety study has started to evaluate its CNS effects.
Newron STARS Fade With Sarizotan Failure
Sarizotan, licensed from Merck KGaA in 2011 for Rett syndrome, was seen as a potential gamechanger for Newron but the termination of the project leaves a huge hole in the Italian group's pipeline.
Finance Watch: iTeos, Pandion And Aspen Show COVID-19 Hasn’t Slowed VC Deals Yet
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Newron Not Seeing Sarizotan STARS Yet
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
Company Information
- Industry
- Diversified
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Breath Therapeutics Holding BV
- Breath Therapeutics GmbH (BREATH)
- Profile Pharma
- Zambon S.p.A.